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Abstract 
Background: Systemic Lupus Erythematosus (SLE) is a common chronic autoimmune disorder that can attack almost all body 
organs leading to the development of significant complications that can be serious and fatal. The incidence of childhood-onset 
systemic lupus erythematosus in the United State is as low as 3 per 1,000,000 children-years with a prevalence that is less than 9 
per 100,000 children. Usually, childhood systemic lupus erythematosus presents acutely with more severe clinical manifestations 
when compared to adulthood systemic lupus erythematosus. 
Methodology: We conducted this review using a comprehensive search of MEDLINE, PubMed, and EMBASE, January 1985, 
through February 2017. The following search terms were used: Systemic lupus erythematosus, manifestation of childhood SLE, 
investigation of childhood SLE, management of childhood SLE, complication of SLE, differences between adult and pediatric 
SLE 
Aim: In this review, we aim to study how SLE manifests differently in pediatric population when compared to adults, the 
laboratory work-up for SLE, and its management.  
Conclusion: Childhood systemic lupus erythematosus is a chronic condition that can be associated with severe outcomes due to 
the involvement of multiple systems in the body. Childhood systemic lupus erythematosus can be more severe than adulthood 
disease, with more activity of the disease, and earlier organs involvement. The most commonly found antibody is anti-nuclear 
antibody. Anti-dsDNA antibodies and anti-smith antibodies have higher specificity for the disease and should thus be tested 
before making a diagnosis. Treatment of systemic lupus in children depends mainly on corticosteroids along with 
immunosuppressants. The most important complication is the development of secondary infections which can be severe due to the 
presence of underlying immunosuppression. 
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INTRODUCTION: 
Systemic Lupus Erythematosus (SLE) is a common 
chronic autoimmune disorder that can attack almost 
all body organs leading to the development of 
significant complications that can be serious and 
fatal. Many physicians call systemic lupus 
erythematosus as ‘the great mimicker’ due to the 
presence of mutual characteristics with many other 
autoimmune disorders. Similarity of lupus to other 
diseases is even more obvious in patients who do not 
develop the classic malar lupus rash, making the 
diagnosis of lupus even more challenging. Systemic 
lupus erythematosus mainly affects females in the 
child-bearing ages, with rare cases occurring in 
younger ages. Actually, the incidence of childhood-
onset systemic lupus erythematosus (cSLE) in the 
United State is as low as 3 per 1,000,000 children-
years with a prevalence that is less than 9 per 100,000 
children [1].  
When studying other populations like blacks, Asians 
and pacific islanders, Hispanics, and Indian 
Americans, higher incidence and prevalence of 
childhood systemic lupus erythematosus can be 
observed. Studies on childhood systemic lupus found 
that the median age of the occurrence of the disease 
in children is between eleven and twelve years, with 
extremely rare cases occurring in children younger 
than five years. Similar to the disease in adults, 
childhood systemic lupus mainly affects females with 
less than 20% of cases being males [2].  
Usually, childhood systemic lupus erythematosus 
presents acutely with more severe clinical 
manifestations when compared to adulthood systemic 
lupus erythematosus. Most previous studies have 
concluded that involvement of renal, hematological, 
and neurological systems is more common and rapid 
in children with systemic lupus erythematosus than 
adults with the disease [1].  
METHODOLOGY: 
• Data Sources and Search terms 
We conducted this review using a comprehensive 
search of MEDLINE, PubMed, and EMBASE, 
January 1985, through February 2017. The following 
search terms were used: Systemic lupus 
erythematosus, manifestation of childhood SLE, 
investigation of childhood SLE, management of 
childhood SLE, complication of SLE, differences 
between adult and pediatric SLE 
• Data Extraction 
Two reviewers have independently reviewed the 
studies, abstracted data, and disagreements were 
resolved by consensus. Studies were evaluated for 
quality and a review protocol was followed 
throughout. 
The study was approved by the ethical board of King 
Abdulaziz University Hospital 
MANIFESTATION OF CSLE: 
Childhood and adulthood systemic lupus 
erythematosus can have many similarities in clinical 
manifestations, with childhood disease being more 
common to cause lymphadenopathy and fever than 
adulthood disease. On the other hand, adults with 
systemic lupus are more likely to present with 
arthritis than children. Developing lupus before or 
after puberty can also lead to different manifestations 
and progression of the disease. For example, 
hemolytic anemia and kidney disease are more likely 
to occur in children who developed lupus before 
puberty, while cutaneous symptoms and 
musculoskeletal involvement are more likely to occur 
early in children who developed lupus following 
puberty [1].  
Similar to adults with lupus, up to 35% of children or 
adolescents who develop systemic lupus 
erythematosus will present with early hematological 
conditions like anemia, lymphopenia, and/or 
thrombocytopenia. Leukopenia is also a common 
presentation with childhood systemic lupus 
erythematosus that can occur in up to 35% of patients 
(while only occur in 18% of adults with lupus). 
Similar to adulthood disease, about 20% of children 
with systemic lupus erythematosus will have positive 
anti-smith antibodies, anti-La antibodies, anti-Ro 
antibodies, and/or anti-ribonucleoprotein antibodies 
[3].  
MUCOCUTANEOUS AND 
MUSCULOSKELETAL MANIFESTATIONS: 
Generally, children with systemic lupus 
erythematosus are significantly more likely to 
develop rashes than adults with the disease, including 
the classical malar rash of lupus. On the other hand, 
the risk of developing painful arthritis (usually non-
erosive) is similar among both adults and children 
with systemic lupus. Many children with systemic 
lupus develop overt arthritis, while adults have a 
higher risk of developing myalgias and arthralgias. 
Additionally, up to 40% of patients with childhood 
systemic lupus erythematosus will develop 
osteopenia (with a z-score that is less than -1.5), 
leading to the development of pathological fractures 
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in about 10% of cases. These rates of osteopenia and 
fractures are generally less than adulthood systemic 
lupus erythematosus, but are somewhat similar to 
postmenopausal systemic lupus erythematosus, where 
about 40% develop osteopenia and 5% develop 
osteoporosis [4].  
CENTRAL NERVOUS SYSTEM 
INVOLVEMENT: 
Involvement of the central nervous system is 
relatively common in patients with systemic lupus 
erythematosus. However, its involvement is usually 
challenging to be detected especially within the early 
course of the disease due to the absence of specific 
investigations (laboratory of imaging) that can early 
detect central nervous system involvement. 
Involvement of the central venous system in 
childhood systemic lupus erythematosus is clinically 
similar to adulthood disease. However, incidence of 
neuropsychiatric involvement is more common in 
children than adults, with up to 70% of patients with 
childhood systemic lupus erythematosus developing 
neuropsychiatric symptoms within the first year 
following diagnosis versus less than 30% of adults 
developing similar symptoms at that early course of 
the disease [5].  
The most common psychiatric disorder in patients 
with childhood systemic lupus erythematosus is 
major depressive disorder. Other clinical 
manifestations of neuropsychiatric involvement in 
childhood lupus include seizures, pseudotumor 
cerebri, and transient ischemic attacks, which have 
similar incidence and prevalence in both children and 
adults with systemic lupus. Some studies have also 
found that about one fourth of children with lupus 
that involved the central nervous system can develop 
cerebrovascular events, which is considered a 
relatively high rate. Additionally, about one fifth of 
patients with childhood lupus involving the central 
nervous system can present with psychosis 
manifesting by visual hallucinations. In fact, 
encephalopathy, psychosis, and chorea are generally 
more common in childhood systemic lupus 
erythematosus than adulthood systemic lupus 
erythematosus [6].   
The development of a cerebral venous thrombosis has 
been found in about one fourth of children with 
systemic lupus, and usually manifests as headaches in 
a patient with positive lupus 
anticoagulant. Moreover, up to 60% of patients with 
childhood systemic lupus erythematosus can develop 
cognitive dysfunctions [6].  
In summary, the involvement of the central nervous 
system in patients with childhood systemic lupus 
erythematosus is not uncommon and can present with 
several clinical manifestations. Different studies have 
reported varying prevalence and incidence, which 
may be attributed to the differences in study designs 
and definitions of the diseases [7]. 
CARDIOPULMONARY MANIFESTATION: 
The most common cardiac complication of systemic 
lupus erythematosus is pericarditis which can be 
present in up to 33% of patients, regardless of their 
age. Adults with systemic lupus can also develop 
acute coronary syndrome and myocardial ischemia. 
However, this is extremely rare in children with lupus 
[7].  
On the other hand, pulmonary complications can 
develop in more than half patients with childhood 
systemic lupus erythematosus. One of the common 
pulmonary complications in both children and adults 
with systemic lupus erythematosus us the 
development of a restrictive lung disease that affects 
the diffusion capacity of the lungs. One rare 
pulmonary complication is ‘shrinking lung 
syndrome’ that is a syndrome of paralysis of the 
diaphragm together with the presence of a restrictive 
pulmonary disease. Shrinking lung syndrome is 
considered extremely rare with only ten cases 
reported in the literature among patients with 
childhood systemic lupus erythematosus, and 150 
cases in adulthood systemic lupus erythematosus. 
The development of a pulmonary hemorrhage in 
either a child or an adult with lupus is associated with 
significantly high mortality [8].  
HEMATOLOGICAL MANIFESTATION: 
The presence of chronic systemic lupus is highly 
correlated with the development of anemia in both 
childhood and adulthood diseases. Incidence of 
anemia increases in younger onset of the disease, 
with up to 77% infants with lupus versus 35% of 
children with lupus. Generally, childhood lupus-
associated anemia is mild or moderate and does no 
lead to severe manifestations. In most cases, it starts 
as a normocytic normochromic anemia that can later 
progress to a microcytic hypochromic anemia as the 
disease progresses [2].  
Leukopenia is also considered to be relatively 
common in both childhood and adulthood systemic 
lupus erythematosus, affecting up to 75% of patients 
at least once throughout the course of their condition. 
However, infants who develop systemic lupus have 
relatively lower risk of developing leukopenia than 
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children with the disease [9].  
On the other hand, neutropenia is relatively rare in 
adulthood systemic lupus erythematosus, but is 
considered more common in children with the disease 
affecting up to 15% of patients. The presence of 
neutropenia in a child or an adult with lupus has been 
found to increase the risk of developing 
thrombocytopenia or central nervous system 
involvement [10].  
Lupus-associated thrombocytopenia is generally 
more prevalent among children with lupus than 
adults. It has been found to be present in about 65% 
of children with lupus, while only present in 25% of 
adults with the disease. In most cases with lupus-
associated thrombocytopenia, antiphospholipid 
antibodies and antiplatelet antibodies are found 
positive in serum [9].  
ENDOCRINAL MANIFESTATION: 
Endocrinal manifestations following a diagnosis of 
systemic lupus erythematosus are common in both 
children and adults with the disease. A previous study 
on children with systemic lupus has found that up to 
85% can develop dyslipidemia [11]. Another study 
has found that abnormal lipid profiles can be present 
in most children and adults with systemic lupus 
erythematosus even before the initiation of their 
corticosteroids therapy. Moreover, both childhood 
and adulthood systemic lupus erythematosus lead to 
the formation of smaller particles of LDL which have 
more atherogenicity. Metabolic syndrome and insulin 
insensitivity have also been observed to be higher in 
patients with lupus (regardless of age) when 
compared to the general population. The increased 
risk of developing diabetes mellitus among children 
with lupus is still debatable. Thyroid conditions can 
also be associated with lupus. A previous study has 
found that up to 20% of children and adults who have 
systemic lupus can develop an autoimmune thyroid 
condition [12].  
Childhood systemic lupus erythematosus has been 
found to cause an average one-year delay in 
menarche in female patients. This delay in menarche 
could be due the disease itself or a side effect of 
corticosteroids treatment. Amenorrhea can develop in 
some patients and has been found in a study in about 
12% of adolescent females with the disease. 
Amenorrhea is generally correlated with the duration 
and severity of the disease. The use of IV 
cyclophosphamide treatment in childhood systemic 
lupus erythematosus can lead to the development of 
ovarian failure. However, rates of ovarian failure are 
generally less common in childhood disease than 
adulthood disease. Female children with systemic 
lupus erythematosus have been found to have a 10% 
risk of developing premature ovarian failure. 
However, this number is not accurate as it was based 
on a single small study [13].  
Similar to adulthood systemic lupus erythematosus, 
childhood disease can lead to abnormalities in the 
semen, the testes, and the levels of gonadotropic 
hormone. These abnormalities even increase in 
patients who receive cyclophosphamide therapy after 
puberty. Abnormalities in the functions of Sertoli 
cells have been found to occur in male children with 
systemic lupus erythematosus [14].  
Immunological Manifestation 
Similar to adulthood systemic lupus erythematosus, 
childhood disease is also marked by the presence of 
circulating anti-nuclear antibodies, which are present 
in all patients. However, the presence of circulating 
anti-nuclear antibodies is not considered specific for 
the disease up to half children with positive anti-
nuclear antibodies were found to have other 
rheumatological diseases liked musculoskeletal pain 
syndrome, rather than systemic lupus erythematosus. 
A previous retrospective cohort that included 110 
children with positive anti-nuclear antibodies and 
followed them for four years found that ten of them 
developed childhood systemic lupus erythematosus 
during the study period [15].  
Anti-dsDNA antibodies, on the other hand, are 
present in about 90% of infants with systemic lupus 
erythematosus. Similar to adults, levels of anti-
dsDNA antibodies can be used to observe the 
progression of the disease in children with lupus. In 
addition, patients with childhood systemic lupus 
erythematosus are more likely to have positive anti-
ribosomal P antibodies and anti-histone antibodies 
than adults with lupus. Previous reports have found 
that up to 42% of children with lupus have positive 
circulating anti-ribosomal P antibodies while only 
11% of adults have positive circulating anti-
ribosomal P antibodies [15].  
Other antibodies that are usually found positive in 
patients with childhood systemic lupus erythematosus 
include anti-Smith antibodies (present in about half 
of the patients), anti-ribonucleoprotein antibodies, 
(present in about 35% of the patients), anti-Ro/SSA 
and anti-La/SSB antibodies (which are present in 
about 15% of patients [9].  
Rheumatoid factor can be also positive in patients 
with childhood systemic lupus erythematosus. 
Previous studies have found that up to 5% of patients 
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have a positive rheumatoid factor at the time of 
diagnosis, and 54% will develop positive results over 
the course of their disease, which is considered 
higher than the number of patients with Juvenile 
Idiopathic arthritis with positive rheumatoid factor 
[9].  
Laboratory Findings 
When children have clinical manifestations that lead 
to suspicion of systemic lupus erythematosus, 
laboratory investigations are generally important to 
confirm or exclude the presence of the disease. The 
most important finding in patients with systemic 
lupus erythematosus is the presence of multiple 
positive antibodies in the serum. As we mentioned 
earlier, Anti-nuclear is the most common antibody in 
patients with lupus. However, its not specific for 
lupus (with a specificity that is less than 36%), 
making it necessary to investigate for the presence of 
other antibodies, like anti double-stranded DNA 
antibodies and extractable nuclear antigens, before 
making a diagnosis. Investigations for other 
antibodies are essential as up to 10% of healthy 
children will have positive circulating anti-nuclear 
antibodies. On the contrary, the specificity of anti-
dsDNA antibodies is relatively high. The best 
specificity for childhood systemic lupus 
erythematosus is with anti-smith antibodies. 
However, they have considerably low sensitivity 
[16].  
Involvement of kidneys can generally be followed 
with levels of anti-dsDNA antibodies and anti-Smith 
antibodies. Females with systemic lupus 
erythematosus who test positive for circulating anti-
Ro antibodies have been found to have a higher risk 
of having a child with neonatal lupus erythematosus, 
which can cause congenital heart block. Therefore, 
these females must be educated about their risks 
before any pregnancy [16].  
Apart from positive antibodies, laboratory findings in 
patients with systemic lupus erythematosus can 
include decreased C3 complement levels, decreased 
C4 complement levels, anemia, leukopenia, 
thrombocytopenia, neutropenia, along with increased 
ESR (with normal C-RP) [16].  
Complications of SLE 
Most patients with systemic lupus erythematosus are 
immunosuppressed for two main reasons [17]:  
1. The disease itself affects and weakens the 
immune system. It also leads to decreased 
circulating complements levels, leukopenia, 
and neutropenia. 
2. The long-term of high doses of 
corticosteroids along with other 
immunosuppressive pharmacological agents. 
Therefore, it is extremely common for these patients 
to develop secondary infections, making infections 
one of the main causes of morbidity and mortality in 
these patients. 
Most lupus-associated infections are caused by 
bacterial organisms, which will lead to an elevation 
of C-RP, that is not usually present in lupus patients 
who do not have infections. Patients with systemic 
lupus erythematosus usually require IV 
antimicrobials treatment. Most lupus patients have 
impaired immunity especially against capsulated 
organism like meningococcus, pneumococcus, 
salmonella, and hemophilus influenza type B [17].  
Viral infections, on the other hand, can cause similar 
clinical manifestations to those observed in a lupus 
flare. Levels of C-RP will be rarely elevated. CMV 
infection in lupus can lead to the development of a 
severe, and potentially fatal, systemic disease. 
Moreover, herpes zoster infections can occur in lupus 
patients, especially those who receive corticosteroids 
treatment, even if they had previously received 
varicella vaccination. Opportunistic infections like 
pneumocystis jiroveci can develop in lupus patients 
who are receiving cyclophosphamide for 
immunosuppression [17].  
MANAGEMENT: 
The management and treatment of children and 
adolescents with systemic lupus erythematosus 
usually requires a coordination between a 
rheumatologist, a primary health care provider, a 
nephrologist (for renal involvement), a psychiatrist, 
and a physical therapist. Aggressive pharmacological 
treatment is usually needed due to the severity of the 
disease. Most pharmacological agents used for the 
treatment of lupus have significant adverse events. 
Therefore, it is important to always balance the 
benefits against the harms before initiating any new 
agent [18].  
Mild cases of lupus can be usually managed with 
hydroxychloroquine or chloroquine. The presence of 
musculoskeletal symptoms can be managed with 
nonsteroidal anti-inflammatory drugs. Corticosteroids 
(oral or intravenous) remain to be among the most 
important drugs in the treatment of systemic lupus. 
Studies suggest that almost all lupus patients will 
receive corticosteroids at least once during the course 
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of their disease [19].  
The use of immunosuppressants is also essential for 
the treatment of systemic lupus erythematosus, 
mainly to decrease the use of steroids. In lupus 
patients with arthritis, methotrexate and azathioprine 
can be used. azathioprine is also effective for cases 
that have vasculitis or serositis. In cases with 
glomerulonephritis, Mycophenolate mofetil can be 
used to induce remission. Cyclophosphamide is 
generally kept for severe cases due to its significant 
adverse events like infertility, malignancies, and 
infections. It can be used in cases of severe central 
nervous system involvement or refractory renal 
involvement [20].  
CONCLUSION: 
Childhood systemic lupus erythematosus is a chronic 
condition that can be associated with severe 
outcomes due to the involvement of multiple systems 
in the body. Childhood systemic lupus erythematosus 
can be more severe than adulthood disease, with 
more activity of the disease, and earlier organs 
involvement. Lupus in children have many 
similarities to lupus in adults regarding clinical 
manifestations, with the presence of some 
differences. The most commonly found antibody is 
anti-nuclear antibody, which is, however, not specific 
for the disease and can be present in many healthy 
children. Anti-dsDNA antibodies and anti-smith 
antibodies have higher specificity for the disease and 
should thus be tested before making a diagnosis. 
treatment of systemic lupus in children depends 
mainly on corticosteroids along with 
immunosuppressants. The most important 
complication is the development of secondary 
infections which can be severe due to the presence of 
underlying immunosuppression. 
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